---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-242583"
form_type: "8-K/A"
ticker: "XENE"
cik: "0001582313"
company_name: "Xenon Pharmaceuticals Inc."
filed_at: "2025-10-17T23:59:59+00:00"
generated_at: "2026-05-17T03:23:33.919455+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Xenon names Tucker Kelly CFO with $540k salary, 225k options, 30k RSUs

## Summary
- Tucker Kelly appointed CFO effective Oct 15, 2025; replaces interim CFO Ian Mortimer who remains CEO.
- Kelly's base salary $540k; eligible for annual incentive up to 45% of base.
- Granted inducement option for 225k shares at $41.90 (Oct 15 close) vesting over 4 years.
- Granted 30k RSUs vesting 25% annually over 4 years.
- Kelly previously CFO of Deciphera, led commercial transition; will support azetukalner launch.

## SEC filing metadata
- accession: 0001193125-25-242583
- form_type: 8-K/A
- ticker: XENE
- cik: 0001582313
- company_name: Xenon Pharmaceuticals Inc.
- filed_at: 2025-10-17T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01, 9.01, 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1582313/000119312525242583/0001193125-25-242583-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1582313/000119312525242583/xene-20251015.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-242583
- JSON: https://secwatch.observer/filing/0001193125-25-242583.json
- Plain text: https://secwatch.observer/filing/0001193125-25-242583.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.